Next Financial Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Next Financial Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$2K	Hold	475	–	–	﹤0.01%	2579
2021 Q3	$2K	Hold	475	–	–	﹤0.01%	2440
2021 Q2	$2K	Hold	475	–	–	﹤0.01%	2370
2021 Q1	$3K	Hold	475	–	–	﹤0.01%	2198
2020 Q4	$3K	Hold	475	–	–	﹤0.01%	2070
2020 Q3	$4K	Buy	+475	New	+$4.16K	﹤0.01%	1881
2020 Q2	–	Sell	-475	Closed	-$1K	–	605
2020 Q1	$1K	Hold	475	–	–	﹤0.01%	1977
2019 Q4	$1K	Hold	475	–	–	﹤0.01%	2245
2019 Q3	$1K	Hold	475	–	–	﹤0.01%	2184
2019 Q2	$2K	Hold	475	–	–	﹤0.01%	2083
2019 Q1	$2K	Hold	475	–	–	﹤0.01%	1423
2018 Q4	$3K	Hold	475	–	–	﹤0.01%	1649
2018 Q3	$6K	Buy	+475	New	+$4.98K	﹤0.01%	1115

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Next Financial Group's ADAP Position: Q4 2021 in Review

Next Financial Group held its Adaptimmune Therapeutics (ADAP) position steady in Q4 2021 at 475 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

Next Financial Group first reported a position in ADAP in Q3 2018 and has held it in 13 quarters since. The position peaked at $6K in Q3 2018. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

Next Financial Group held 475 shares of Adaptimmune Therapeutics worth $2K as of Q4 2021.
Next Financial Group left its Adaptimmune Therapeutics share count unchanged in Q4 2021.
Adaptimmune Therapeutics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2579 holding.
Next Financial Group first reported a position in Adaptimmune Therapeutics in Q3 2018 and has held it in 13 quarters since.
Next Financial Group's Adaptimmune Therapeutics position peaked at $6K in Q3 2018.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.